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Abstract 
Background: Pathogenic bacteria easily develop resistance to conventional antibiotics so that even relatively new 
molecules are quickly losing efficacy. This strongly encourages the quest of new antimicrobials especially for the 
treatment of chronic infections. Cationic antimicrobial peptides (CAMPs) are small positively charged peptides with an 
amphipathic structure, active against Gram-positive and Gram-negative bacteria, fungi, as well as protozoa.
Results: A novel (CAMP)-like peptide (VLL-28) was identified in the primary structure of a transcription factor, Stf76, 
encoded by pSSVx, a hybrid plasmid–virus from the archaeon Sulfolobus islandicus. VLL-28 displays chemical, physi-
cal and functional properties typical of CAMPs. Indeed, it has a broad-spectrum antibacterial activity and acquires a 
defined structure in the presence of membrane mimetics. Furthermore, it exhibits selective leakage and fusogenic 
capability on vesicles with a lipid composition similar to that of bacterial membranes. VLL-28 localizes not only on the 
cell membrane but also in the cytoplasm of Escherichia coli and retains the ability to bind nucleic acids. These findings 
suggest that this CAMP-like peptide could exert its antimicrobial activity both on membrane and intra cellular targets.
Conclusions: VLL-28 is the first CAMP-like peptide identified in the archaeal kingdom, thus pointing to archaeal 
microorganisms as cell factories to produce antimicrobial molecules of biotechnological interest. Furthermore, results 
from this work show that DNA/RNA-binding proteins could be used as sources of CAMPs.
© 2015 Notomista et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Broad-spectrum antimicrobial peptides represent an effi-
cient weapon of the innate immune system in vertebrates 
and other organisms together with the adaptive immune 
response [1, 2]. An example of such molecules is repre-
sented by cationic antimicrobial peptides (CAMPs), i.e. 
small positively charged peptides with an amphipathic 
structure. CAMPs are active against Gram-positive and 
Gram-negative bacteria, fungi, as well as protozoa [1]. 
Although their mechanism of action has been extensively 
investigated [3–5], to date it has not been fully unraveled. 
Targets of CAMPs may be either bacterial membranes 
or diverse intracellular molecules; however some pep-
tides can operate through complex mechanisms that can 
involve multiple targets [6].
CAMPs usually kill bacteria either by disrupting the 
integrity of cell membrane or by altering its potential. 
Their net positive charge drives the initial adsorption 
onto the extracellular surface of bacterial membranes 
(which is very rich in negatively-charged molecules/
lipids) while their amphipathic nature fosters the inser-
tion into the membrane [7, 8]. So far, several models have 
been proposed to explain the mechanism of the mem-
brane interaction such as the barrel stave channel, the 
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toroidal pore, the carpet and aggregate models [9–11]. 
For example, the antibacterial mechanisms of alame-
thicin, magainin II and polymyxin B [12–14] have been 
reported to involve barrel stave channels, toroidal pores 
and carpet mechanisms, respectively [6]. Membrane dis-
aggregation causes either cellular contents to leak out 
and/or alteration of the bilayer composition thus lead-
ing to impaired membrane functions and eventually to 
cell death [15]. Furthermore, many antibacterial peptides 
have been reported to translocate across the cytoplasmic 
membrane thus affecting the functionality of intracellular 
targets [16, 17]. Typical examples of this kind are Buforin 
II, a well-known DNA-binding CAMP from the Asian 
toad, Bufo bufo gargarizans [18], and PR-39, which inhib-
its DNA, RNA as well as protein synthesis [6].
Surprisingly, several eukaryotic proteins (e.g. haemo-
globin, thrombin, lactoferrin, lysozymes, histone-like 
proteins and ribonucleases) with functions not directly 
related to host defense mechanisms, can be sources of 
“cryptic” CAMPs that are released after a partial proteo-
lytic processing carried out by bacterial and/or host pro-
teases [19, 20].
Interestingly, Schmidtchen and co-workers demon-
strated that heparin-binding motifs of endogenous pro-
teins exhibit antimicrobial activity [21]. They suggested 
that the regular spacing of cationic residues in heparin-
binding peptides generates amphipathic/cationic struc-
tures closely resembling those of typical CAMPs. Starting 
from their work, we hypothesized that several anionic-
polymers-binding proteins could be used as sources of 
CAMPs, including nucleic acid binding proteins such 
as transcriptional factors or proteins involved in stabi-
lization or repair of DNA and RNA. This hypothesis is 
supported by two well-known examples: (1) Buforine II, 
which is a fragment of the N-terminus of Histone H2A 
released by proteolysis [22]; (2) the peptide HP(2-20), 
derived from N-terminus of Helicobacter pylori riboso-
mal protein L1, which effectively kills Candida albicans 
and other fungi by damaging membranes [23]. With 
this purpose we have employed a new in silico method 
for the identification of potential cryptic CAMPs based 
on the correlation between antimicrobial activity and 
charge/hydrophobicity (Pane et  al. manuscript submit-
ted). This method has been applied to seek for cryptic 
CAMPs in the primary structure of host and viral DNA/
RNA-binding proteins from Sulfolobus. Indeed, micro-
organisms belonging to this archaeal genus have been 
proven to be suitable for the production of unique stable 
products with high technological value, because of their 
ability to grow under extreme conditions [24, 25]. Herein 
we report a thorough characterization of the antimicro-
bial VLL-28 peptide identified in the primary structure of 
Stf76 protein, a transcription factor encoded by pSSVx, 
a hybrid plasmid–virus from the archaeon Sulfolobus 
islandicus. Stf76 solution structure was recently resolved 
by nuclear magnetic resonance (NMR) spectroscopy and 
residues involved in the interaction with DNA were iden-
tified [26]. VLL-28 antimicrobial activity, its behaviour in 
the presence of either membrane mimetics or artificial 
vesicles and its DNA/RNA binding capability have been 
analysed by means of different spectroscopic and bio-
chemical techniques.
Results
Identification of VLL‑28
VLL-28 is a fragment of Stf76 protein, a transcription 
factor encoded by pSSVx, a hybrid plasmid–virus from 
the archaeon S. islandicus [26]. This DNA-binding pro-
tein adopts a winged helix-turn-helix fold and NMR 
chemical shift perturbation analysis has been used to 
identify residues responsible for DNA interaction. Sev-
eral residues, showing significant chemical shift and/or 
intensity changes either in the absence or presence of 
the target DNA, are clustered in a region correspond-
ing to helix 3 and to the “wing” i.e. the long hairpin 
between helices 3 and 4 (Fig. 1). Even more intriguingly 
this region shows an amino acid composition similar 
to that of CAMPs, indeed it is very rich in basic and 
hydrophobic residues as highlighted in Fig. 1. A new in 
silico method (Pane et  al. manuscript submitted) has 
been employed for the identification of cryptic CAMPs 
Fig. 1 Sequence and NMR structure (pdb code: 2MLG) of Stf76. 
Asterisks indicate residues showing significant chemical shift and/
or intensity changes in the absence or presence of the target DNA. 
Position of helices and strands is indicated by red and cyan lines, 
respectively, above the sequence. Position of VLL-28 is indicated by a 
white line below the sequence. Residues in the sequence are coloured 
according to the following scheme: blue, basic (R, K); red, acidic (D, E); 
yellow, polar uncharged (N, Q, S, T, G); green, hydrophobic (W, F,Y, L, V, I, 
M, A, P); cyan, histidine; olive green, cysteine. In the NMR structure only 
residues of VLL-28 are coloured according to the same scheme.
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that are hidden inside the sequences of large precur-
sors. This method assigns to peptides an antimicro-
bial score based on their charge, hydrophobicity and 
length and on some strain-dependent weight factors. 
Such antimicrobial score is proportional to the antimi-
crobial activity of CAMPs, at least for score values in 
the range 6.5–9.5. Scores lower than 6.5 are not signifi-
cant, whereas for score values higher than 10 the lin-
ear relationship is no longer valid. The selected peptide, 
VLL-28, is the shortest peptide exhibiting a relative 
maximum in the score profile shown in Fig. 2. Its score 
(13.0) is above the linearity range therefore, according 
to the cited method, a further elongation of the peptide 
would not result in a significant increase of the antimi-
crobial activity. VLL-28 has a net charge of +8 at pH 
7 and 43% of hydrophobic residues, hence, it closely 
resembles CAMPs in length, charge and hydrophobic 
residues content.
Fig. 2 Isometric plot showing the antimicrobial score values of peptides from 12 to 40 residues in the sequence of Stf76 obtained using param-
eters optimized for strain S. aureus C623. Peptide length is on the x axis and position of the peptides inside the sequence on the y axis. Colours were 
used to highlight antimicrobial score values higher than 6.5 corresponding to theoretical MIC values lower than 200 μM. The position of VLL-28 is 
indicated by the red arrow.
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Circular dichroism characterization
Circular dichroism (CD) spectroscopy was employed 
to assess the structure of VLL-28 in aqueous solution 
either in the presence of the helix-inducing solvent TFE 
or detergents with varying head groups (anionic, Sodium 
Dodecyl Sulphate (SDS); or zwitterionic, n-dodecyl phos-
phatidylcholine (DPC) [27]).
It is well known that whereas DPC micelles simulate 
eukaryotic cell membranes, which are generally rich in 
zwitterionic phospholipids, those made of SDS mimic the 
negatively charged lipids found in bacterial membranes. 
Indeed, SDS micelles have a flexible, anionic exterior 
and a hydrophobic interior. In aqueous buffer, the pep-
tide typically adopted a ‘random coil’ structure indicated 
by a minimum near 200 nm (Fig. 3, continuous line). The 
addition of 25% TFE induced α-helical formation, charac-
terized by a spectrum with a maximum at around 190 nm 
and two minima at around 208 and 222 nm (Fig. 3). Fur-
ther addition of TFE did not modify VLL-28 spectrum as 
showed by the CD signal at 222 nm as function of TFE% 
(insert of Fig.  3). Likewise, the addition of detergents 
such as SDS or DPC prompted α-helical formation gen-
erating a transition from a disordered to an helical struc-
ture as showed in Fig. 3. The prediction of the secondary 
structure percentages from the CD spectra, calculated by 
CDPRO software, showed that VLL-28 assumes similar 
secondary structures in the presence of 25% TFE or DPC, 
accounting for about 40 and 45% alpha-helix, respec-
tively. The presence of SDS has a minor effect on VLL-28 
conformation, since it displays only 20% helical content.
EMSA assays
Since the sequence of VLL-28 is included in the DNA-
binding motif of the transcription factor Stf76, we 
resolved to investigate whether VLL-28 had retained the 
capability to bind to the same DNA sequences as the 
protein source. Stf76 has been shown to interact specifi-
cally with two DNA regions (site A and site B) located 
within its own promoter, though with differential affini-
ties (site A  >  site B). Both single and double stranded 
DNAs, issued from the sequence of site A, were tested as 
substrates in EMSA experiments. When a fixed quantity 
of a radiolabelled ds DNA probe correspondent to site A 
was incubated with increasing amount of VLL-28, a dis-
tinct complex, that remained at the top side of the gel, was 
observed (Fig.  4a). This complex probably resulted from 
either non-specific VLL-28—DNA interactions or from 
the formation of aggregates since the same result was 
obtained with a DNA fragment unrelated to the binding 
site of Stf76 (not shown). To test whether VLL-28 showed 
also affinity toward single stranded DNA, a 36 mer oligo-
nucleotide was used as substrate. A complete titration of 
the probe was observed at lower concentration of VLL-
28, thus demonstrating that it displays a higher affinity for 
ssDNA than for dsDNA. In this case the shifted signal was 
hardly visible because of the formation of high molecular 
weight DNA/VLL-28 complexes that were unable to enter 
into the gel matrix (Fig. 4b). As negative control, the same 
set of experiments was performed with a peptide (named 
GABA) which exhibits an amino acid composition similar 
to that of VLL-28. Additional file 1: Figure S1a shows that 
GABA is unable to interact with dsDNA.
Since CD experiments demonstrated that TFE induced 
helical conformation, EMSA experiments were per-
formed by pre-incubating VLL-28 with 30% TFE to test 
whether the acquisition of a defined three dimensional 
structure could increase its binding efficiency. No rel-
evant differences were observed in the intensity of the 
retarded band, thus indicating that TFE has negligible 
effects on the binding of VLL-28 to single strand sub-
strate (Additional file 1: Figure S1b).
Finally, RNA was tested as substrate in gel retardation 
shift experiments. Interestingly, VLL-28 was able to form 
high molecular weight complexes also with RNA mole-
cules that stuck in the wells of the agarose gel used for the 
electrophoretic mobility assay (Fig.  4c). Taken together 
these results suggest that VLL-28 forms unspecific high 
molecular weight aggregates upon interaction with 
DNAs or RNAs molecules.
VLL‑28 antimicrobial activity and MIC90 determination
To test its anti-microbial activity, VLL-28 was assayed at 
two different concentrations (0.3 and 3  μM) on several 
bacterial strains and on C. albicans (Fig. 5). VLL-28 has 
a broad spectrum of action, and it is active at a quite low 
concentration. The strongest activity was observed for E. 
coli cells while all the other strains tested (including C. 
Fig. 3 Far UV CD spectra of VLL-28 alone (continuous line) or in the 
presence of TFE (white circle), DPC (filled triangle) and SDS (filled 
square). In the Inset molar ellipticity at 222 nm versus increasing TFE 
concentration.
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albicans) turned out to be sensitive at higher concen-
tration (3  μM). The most resistant was a Pseudomonas 
aeruginosa strain isolated from a patient suffering from 
cystic fibrosis.
VLL-28 MIC90 for the different strains treated was cal-
culated (see “Methods”) and reported in Table 1.
VLL-28 antimicrobial activity was compared to that of 
peptide GKY20, a well-known “cryptic” CAMP derived 
from the C-terminus of human thrombin, which is effec-
tive against several microbial strains [28]. Interestingly, 
the activity of VLL-28 is comparable to that of GKY20 
when E. coli was used as indicator strain, as shown in 
Additional file 2: Figure S2.
E. coli cell fractionation
A fluoresceine labelled derivative of VLL-28 (VLL-28*) 
was used to determine the cellular localization of the 
peptide in E. coli. Antimicrobial activity of VLL-28* was 
found to be similar to that of VLL-28 (data not shown). 
Bacterial cells were treated with VLL-28* at a concen-
tration of 10 μM for 4 h, since the growth of E.coli cells 
was completely inhibited under these conditions (data 
not shown). Afterwards, E. coli cells were fractionated 
in cytosolic and membrane fractions. Proteins of each 
fraction extracted after VLL-28* treatment, or untreated, 
were loaded on an 18% SDS-PAGE (Fig.  6). VLL-28* 
resulted to be mainly localised in the membrane fraction 
Fig. 4 EMSA analysis of VLL-28 binding to dsDNA (a), ssDNA (b) and RNA (c). W stands for bound and aggregated DNA that remained in the wells of 
the gel. Binding to the labelled ds and ss probe was tested over a wide range of increasing concentration of VLL-28 until a complete titration of the 
free probe was observed which occurred at a lower VLL-28 concentration in the presence of ssDNA probe (compare a and b).
Fig. 5 Antimicrobial activity assay of VLL-28. The peptide was added at two concentrations (0.3 and 3 μM) to cell samples of E. coli, three different P. 
aeruginosa strain (PAOI, PA14 and RP73), S. aureus, B. subtilis AZ54 and C. albicans. Untreated cells of each strain represent the control (0). The stand-
ard deviation was always lower than 5%. Values are reported as mean ± SD of three different experiments.
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of treated cells, thus indicating that the peptide interacts 
with the bacterial membranes. A signal corresponding 
to VLL-28* was also present in the cytoplasmic fraction 
indicating that a certain amount of the peptide is able to 
enter into the bacterial cells.
Fusogenic properties of VLL‑28
To investigate fusogenic activity of VLL-28, a mix of 
NBD- and Rho-labeled phosphatidylethanolamine was 
used. The two fluorescent molecules play as the donor 
(NDB) and acceptor (Rho) in the fluorescence energy 
transfer experiment, respectively. Labeled (with NBD and 
Rho) and unlabeled Large unilamellar vesicles (LUVs) 
were mixed, before adding an increasing amount of pep-
tide. Dilution of the fluorescent-labeled vesicles caused by 
peptide-mediated membrane fusion resulted in a reduc-
tion in the fluorescence energy transfer efficiency and 
therefore in the dequenching of the donor fluorescence. 
Different molar ratios (VLL-28/lipids) have been tested 
to evaluate the fusogenic activity of VLL-28 (Fig. 7). The 
peptide showed a significantly greater fusogenic activity 
in DOPE/DOPG LUVs compared with that in DOPC/
DOPG LUVs whereas no activity was found in PC. Since 
DOPE/DOPG mimics the membrane lipid composition 
of E. coli toward which the peptide showed the highest 
antibacterial activity, these results are in good agreement 
with the antibacterial data.
Leakage assays
A content-mixing assay was employed to monitor any 
mixing of internal vesicle components caused by vesicle 
exposure to VLL-28. Release of ANTS and DPX from 
vesicles is commonly used as a measure of bilayer per-
turbation and interpreted as index of “transient pore 
formation” [29]. Vesicle content mixing is evidenced by 
a decrease in fluorescence intensity when vesicles encap-
sulating the fluorescent cargo (e.g., ANTS) merge their 
content with those containing the quencher (e.g., DPX). 
Figure 8 shows that leakage occurs over the same range 
of P/L ratio in which VLL-28 shows the highest fusogenic 
activity, i.e. when lipid mixing occurs. The agreement 
between the leakage and the fusogenic assays gives full 
confidence to the finding that VLL-28 causes peptide- 
induced pore formation.
Quenching of tryptophan by BrPC
A tryptophan residue naturally present in the sequence 
of proteins or peptides can serve as an intrinsic probe to 
localize the peptide within a membrane. In particular, the 
position and the depth of the peptide inside the bilayer 
can be investigated by measuring the relative quench-
ing of the fluorescence of the Trp residue by the probes 
11,12-Br-PC, 9,10-Br-PC, and 6,7-Br-PC, which differ in 
the position of the quencher moiety along the hydrocar-
bon chain. 6,7-Br-PC is a better quencher for molecules 
Table 1 VLL-28 concentration causing a 90% growth inhi-
bition (MIC90) of the listed strains
Strains MIC90 (µM)
E. coli DH5α 1.5
B. subtilis AZ54 3
P. aeruginosa PAOI 3
S. aureus ATCC 6538P 3
P. aeruginosa RP73 6
P. aeruginosa PA14 3
C. albicans ATCC 10231 3
Fig. 6 SDS-PAGE analysis of membrane and cytoplasmic fractions 
of E. coli cells. Fluorescent peptide VLL-28* used as positive control 
(lane 1); protein molecular weight marker (lane 2); membrane fraction 
treated (lane 3) or untreated (lane 4) with VLL-28*; cytoplasmic frac-
tion treated (lane 5) or untreated (lane 6) with VLL-28*.
Fig. 7 Lipid mixing: VLL-28 interaction with LUVs of different compo-
sition. The dose dependence is reported and each trace represents an 
average of three independent experiments.
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near or at the interface, while the other two are better 
probes for molecules buried deeply inside the membrane 
[30]. The largest quenching of VLL-28 tryptophan fluo-
rescence was observed with 9,10-Br-PC vesicles (Fig. 9), 
while slightly less quenching was observed with 6,7-Br-
PC and 11,12-Br-PC. These results clearly indicate that, 
upon binding to vesicles, VLL-28 partially inserted into 
the membrane bilayer.
Discussion
The main aim of this work was to prove that the genomes 
of Sulfolobus and of its infecting viruses could be source 
for antimicrobial molecules such as CAMP-like peptides. 
In agreement with this purpose we have analysed several 
archaeal host and viral DNA/RNA binding proteins as 
potential source of CAMPs and selected a transcription 
factor encoded by the genome of pSSVx, a hybrid plas-
mid–virus from the archaeon S. islandicus, whose DNA 
binding motif is mainly located in a single stretch of 
about 30 residues. A 28-residue peptide (VLL-28), which 
includes 7 positively-charged and 12 hydrophobic resi-
dues, was indicated as a potential CAMP through a bio-
informatic approach.
The characterization of VLL-28 showed that it pos-
sesses all the typical features of CAMPs. First of all, 
VLL-28 turned out to be a broad-spectrum antimicro-
bial peptide, being active on Gram+ and Gram− bacteria 
including some clinically relevant strains, such as P. aer-
uginosa and S. aureus. Moreover it also showed antifun-
gal activity against C. albicans. Secondly, VLL-28 shows 
several chemical-physical properties resembling those 
of CAMPs. In particular, CD studies demonstrated that 
VLL-28 is unstructured in solution, whereas it acquires 
a well-defined secondary structure in the presence of 
membrane mimetics, like TFE (20–25%), DPC and SDS. 
The alpha-helix percentage of VLL-28 is in good agree-
ment with that adopted by this fragment in the par-
ent protein (Stf76) whereas extended and coil structure 
percentage is slightly lower. This is not surprising if we 
consider that the peptide includes only part of the long 
beta hairpin of STf76 (Fig. 1) and it does not contain the 
disulphide that anchors the end of the hairpin with the 
helix alpha2. In addition both the leakage and fusogenic 
assays showed that the peptide interacts and selectively 
damages the DOPC/DOPG (4/1) or DOPE/DOPG (4/1) 
LUVs, which mimic bacterial membranes likely inducing 
the formation of a pore.
Less obviously, we found that VLL-28 was still able to 
bind nucleic acids even if, differently from the parent 
protein, it displayed a preferential binding to ssDNA or 
RNA and the propensity to form unspecific high molecu-
lar weight aggregates upon interaction with nucleic acids. 
In agreement with these findings, in E. coli cells VLL-28 
was found to be not entirely located in the membrane 
but also in the cytoplasm though at lower concentra-
tion. This suggests that antimicrobial properties of this 
peptide could be due to a multi-layered killing mecha-
nism involving both membrane damages and nucleic acid 
binding as demonstrated for buforin II [18]. However this 
aspect will require further investigations to be completely 
unraveled.
Currently, it is less clear if the activity of VLL-28 
has any physiological relevance. It is well known that 
some Archaea produce effective antimicrobial (poly)
peptides called archaeocins, directed against compet-
ing and related organisms [31–34] that are functionally 
equivalent to the well-characterized bacteriocins [35] 
but are unrelated to the CAMPs. Considering the sub-
stantial differences between Archaea and Bacteria in the 
Fig. 8 Leakage of ANTS/DPX: VLL-28 interaction with DOPE/DOPG 
LUVs. The dose dependence is reported and each trace represents an 
average of three independent experiments.
Fig. 9 Tryptophan fluorescence spectra for VLL-28 in buffer and in 
the presence of the probes 11,12-Br-PC, 9,10-Br-PC, and 6,7-Br-PC.
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composition and in the structure of the membranes it is 
unlikely that VLL-28 could play a physiological role as 
CAMP against Archaea members.
Conclusions
In this work, we have identified and in-depth studied 
the first CAMP-like peptide from the archaeal king-
dom. The peptide is active against Gram+, Gram− bacte-
ria as well as C. albicans. The functional and structural 
characterization of VLL-28 allowed to hypothesize a 
multi-layered mechanism of action involving both mem-
brane damages and nucleic acid binding. Furthermore, 
VLL-28 is expected to be inherently stable because of 
its thermophilic origin and therefore it is foreseen a suc-
cessful employment of this peptide in several biological 
applications.
Methods
Materials, peptides
VLL-28 peptide (VLLVTLTRLHQRGVIYRKWRHFS-
GRKYR), its fluoresceinated derived form (VLLVTLTRL-
HQRGVIYRKWRHFSGRKYRGK*) (VLL-28*), bearing 
the chromophore fluorescein coupled to the last lysine 
residue, and peptide GKY20 (GKYGFYTHVFRLK-
KWIQKVI) were synthetized and purified to 95% homo-
geneity by Inbios (Napoli, Italy) as assessed by LC–MS. 
GABA peptide was the same used elsewhere [36].
The phospholipid phosphatidylcholine (PC), 1,2-diole-
oyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-
sn-glycero-3-phospho-(1′-rac-glycerol) (DOPG), 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 
1-hexadecanoyl-2-(6,7-dibromooctadecanoyl)-sn-glycero-
3-phosphocholine (6,7 Br-PC), 1-hexadecanoyl-2-(9,10-
dibromooctadecanoyl)-sn-glycero-3-phosphocholine (9,10 
Br-PC), 1-hexadecanoyl-2-(11,12-dibromooctadecanoyl)-
sn-glycero-3-phosphocholine (11,12 Br-PC) 
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-
(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD-PE), 1,2-dimyris-
toyl-sn-glycero-3-phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) (RHO-PE) were purchased from 
Avanti Polar Lipids (Birmingham, AL, USA). Triton-X100, 
8-Aminonaphthalene-1,3,6-trisulfonic acid disodium salt 
(ANTS), p-Xylene-bis(N-pyridinium bromide) (DPX) were 
obtained from Sigma (St. Louis, MO, USA).
Circular dichroism (CD) spectroscopy
Far-UV CD spectra were recorded on a Jasco J-810 spec-
tropolarimeter (JASCO Corp) equipped with a PTC-
423S/15 peltier temperature controller in the wavelength 
interval of 190–260 nm.
Experiments were performed using a 50  μM VLL-28 
solution (50  mM phosphate buffer, pH 7.5) in a 0.1  cm 
path-length quartz cuvette. Spectra were acquired at 
20°C according to the following parameters data pitch of 
0.2 nm, 20 nm/min scan speed, 1.0 nm bandwidth and 8 s 
response. CD spectra of the peptide were collected also 
in the presence of different concentrations (v/v) of TFE 
(2,2,2-Trifluoroethanol) (10, 15, 20, 25, 30, 40 and 50%) at 
a 20 μM concentration of VLL-28. Similar analyses were 
performed in the presence of SDS and DPC (n-dodecyl 
phosphatidylcholine). In particular, CD spectra were 
registered after incubation at room temperature with 
20 mM SDS or DPC (molar ratio 1:1,000) for 90 min. The 
spectra were obtained subtracting the buffer contribu-
tion by using the Spectra Manager software. A prediction 
of the secondary structure content was performed with 
CDPRO.
EMSA assays
VLL-28 was tested for its ability to bind to ds- (double-
stranded) and ss- (single-stranded) DNA as well as to 
RNA substrates through band-shift assay (EMSA). The 
ds-probe used was a 52  bp-long sequence encompass-
ing the DNA binding motif of the parent Stf76 protein 
[26]. This DNA fragment was PCR-amplified according 
to Contursi et al. [26]. Binding to the ss-probe was tested 
by using a 36 nt-long 32P labelled oligodeoxynucleotide 
(5′-GGAAACAGTATTAATAAAGTGTTAATCCTA 
TTACCC-3′). All EMSA assays were conducted at 37°C 
in the assay buffer [20 mM Tris–acetate (pH 8.0), 50 mM 
potassium acetate, 10  mM magnesium acetate, 1  mM 
DTT (dithiothreitol) and 5% (v/v) glycerol] in the pres-
ence of 1 μg of salmon sperm DNA (as unspecific com-
petitor) and by adding labelled probes at concentrations 
within the range of 5–10 nM. Binding reactions were per-
formed with increasing amounts of VLL-28 (25–300 μM) 
for 30 min at 37°C and analyzed on 10% polyacrylamide 
gel run in 0.5× TBE (Tris–Borate-EDTA buffer). Gels 
were transferred onto filter paper, dried and revealed 
both by Molecular Dynamics Bio-Rad PhosphorImager 
and autoradiography. Alternatively, a total RNA sample 
was prepared as described elsewhere [37] and used as 
substrate. Reactions were set up with 2 μg of RNAs and 
25–100 μM of VLL-28 and analyzed on 1% agarose gel in 
TAE (Tris–acetate-EDTA buffer).
VLL‑28 antimicrobial activity
Aliquots of overnight cultivated Gram-positive S. aureus 
ATCC 6538P, B. subtilis AZ54, and Gram-negative E. 
coli DH5α and C. albicans ATCC 10231 cultures were 
re- inoculated in fresh Luria–Bertani (LB) broth. P. aer-
uginosa PAOI, PA14 and RP73 (clinical isolated from 
Cystic Fibrosis patients), were, instead, grown in Tryp-
tic Soy broth (TSB). Cells were pelleted by centrifuga-
tion, washed twice with Phosphate-buffered saline (PBS) 
and finally diluted at 1:100 in PBS. 500 μL aliquots of 
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cell suspensions were incubated for 4 h at 37°C with dif-
ferent concentrations of peptide (VLL-28) in the range 
0.3–3 μM. The same amount of peptide-free buffer and 
cells were used as negative control. Peptide-treated bac-
terial and fungal suspensions were plated either on LB 
agar or on Tryptic Soy Agar (TSA, for Pseudomonas 
strains), incubated overnight at 37°C, and colony forming 
units per millilitre (CFU)/mL was determined after each 
treatment. Each experiment was carried out in triplicate 
and final results are the average of three independent 
experiments.
MIC90 (minimal inhibitory concentration which inhib-
its 90% of cells) of VLL-28 for the different strains tested, 
was determined according to micro-dilution method 
established by Clinical and Laboratory Standards Institute 
(CLSI). In brief, 95  µL of cation-adjusted Mueller–Hin-
ton broth supplemented with different concentrations of 
VLL-28 ranging from 50 to  0.1  µM were added to each 
well of a 96-well micro-titer plate. 5 µL of bacterial or fun-
gal suspensions were added to each well to yield a final 
concentration of about 5 × 105 cells/mL. Growth inhibi-
tion was determined after 20 h of incubation at 35 ± 2°C. 
[National Committee for Clinical Laboratory Standards. 
Performance standards for antimicrobial susceptibility 
testing; Nint informational supplement. NCCLS docu-
ment M100-S9 (ISBN1-56238-358-2). NCCLS, 940 West 
Valley Road, Wayne, Pa19087-1898 USA, 1999].
E. coli cell fractionation
Bacterial cells were grown in 10  mL of medium until 
reaching an OD600 of 1.0, before being pelleted and re-
suspended in 0.5 mL of periplasting buffer (20% sucrose, 
1  mM EDTA), containing 30,000  U/mL of Ready-Lyse 
lysozyme (Epicentre Technologies, Madison, WI, USA). 
After incubation on ice for 5 min, spheroplasts were pel-
leted by centrifugation at 12,000×g for 2  min and the 
supernatant was collected as periplasmic fraction. Pelleted 
spheroplasts were, instead, lysed in 1 mL of water contain-
ing 400 U/mL of Omnicleave Endonuclease (Epicentre 
Technologies). Samples were incubated for 5 min at room 
temperature and briefly sonicated at 30–40% amplitude 
(maximum power 300  W) with a Sonics vibracell VCX-
130 (Sonics & Materials, Inc., Newtown, CT, USA). Whole 
cells were removed by centrifugation at 12,000×g whereas 
supernatant were further centrifuged at 138,000×g for 
1 h, to recover cell membranes from the cytoplasmic frac-
tion. Membrane containing pellets were eventually re-sus-
pended in 0.5% Sarkosyl (Ciba-Geigy Corp., Summit, NJ, 
USA), 10 mM Tris–HCl and 5 mM EDTA.
Liposome preparation
Large unilamellar vesicles (LUVs) consisting of DOPC/
DOPG 4/1, DOPE/DOPG 4/1 and PC, and when 
necessary containing Rho-PE and NBD-PE, were pre-
pared according to the extrusion method by Hope et al. 
[38] in 5 mM Hepes, 100 mM NaCl, pH 7.4. Lipids were 
dried from a chloroform solution with a nitrogen-gas 
stream and lyophilized overnight. Dry lipid films were 
re-suspended in buffer by vortexing; the lipid suspen-
sion was freeze-thawed 6 times and extruded 20 times 
through polycarbonate membranes with 0.1  μm diam-
eter pores to produce large unilamellar vesicles. When 
necessary, small unilamellar vesicles (SUVs) were pre-
pared using the same protocol, but the final extrusion 
was substituted by sonication for 30 min. The final lipid 
concentration was 1 mM.
Lipid mixing assays
Membrane lipid mixing was monitored using resonance 
energy transfer assay as previously reported [39] on 
a mix of labelled and unlabelled DOPC/DOPG (4/1), 
DOPE/DOPG (4/1) and PC LUVs. Lipid mixing experi-
ments were repeated at least three times, and results 
were averaged. All experiments were performed at room 
temperature.
Leakage assays
The ANTS/DPX assay [40, 41] was used to measure the 
ability of the peptide to induce leakage of ANTS/DPX 
pre-encapsulated in liposomes. Details of this assay can 
be found elsewhere [42]. To start up the leakage experi-
ment, a 2 mM peptide stock solution (5 mM Hepes and 
100 mM NaCl, pH 7.4) was added to a stirred vesicle sus-
pension (0.1 mM lipid) at 37°C.
Tryptophan quenching experiments with Br‑PC
Tryptophan is sensitive to environmental perturbation 
and has been previously utilized to evaluate peptide 
localization in biological membranes. Emission spec-
tra of VLL-28 in the absence or presence of target vesi-
cles (DOPE/DOPG 4/1) were recorded between 300 and 
400 nm using an excitation wavelength of 295 nm. Br-PC 
employed as quencher of tryptophan fluorescence is suit-
able for probing membrane insertion of peptides, since it 
acts over a short distance and it does not drastically per-
turb the membrane [43]. The peptide was added (final 
concentration of 0.5 μM) to 2 ml of buffer (5 mM Hepes, 
100  mM NaCl pH 7.4) containing 20  μL (50  mM) of 
Br-PC/Chol SUV, thus establishing a lipid:peptide molar 
ratio of 100:1. After 2  min of incubation at room tem-
perature, a tryptophan emission spectrum was recorded 
with excitation set at 295 nm. SUV composed of DOPE/
DOPG 4/1and containing 25% of either 6,7 Br-PC, 9,10 
Br-PC, or 11,12 Br-PC were used. Three separate experi-
ments were conducted. In control experiments, the pep-
tide in DOPE/DOPG 4/1 SUVs without Br-PC was used.
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